Olive JF, Qin Y, DeCristo MJ, Laszewski T, Greathouse F, McAllister SS. Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies. PLoS One. 2018;13(6):e0198790. doi:10.1371/journal.pone.0198790
Juratli TA, McCabe D, Nayyar N, et al. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018;136(5):779-792. doi:10.1007/s00401-018-1899-7
Danai LV, Babic A, Rosenthal MH, et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 2018;558(7711):600-604. doi:10.1038/s41586-018-0235-7
Sellar RS, Jaiswal S, Ebert BL. Predicting progression to AML. Nat Med. 2018;24(7):904-906. doi:10.1038/s41591-018-0114-7
Tian C, Huang Y, Clauser KR, et al. Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells. Nat Commun. 2021;12(1):2328. doi:10.1038/s41467-021-22490-9
Hermle T, Schneider R, Schapiro D, et al. and Mutations Implicate RAB5 Regulation in Nephrotic Syndrome. J Am Soc Nephrol. 2018;29(8):2123-2138. doi:10.1681/ASN.2017121312
Eulenberg P, Köhler N, Blasi T, et al. Reconstructing cell cycle and disease progression using deep learning. Nat Commun. 2017;8(1):463. doi:10.1038/s41467-017-00623-3
Tyekucheva S, Bowden M, Bango C, et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017;8(1):420. doi:10.1038/s41467-017-00460-4
Christov M, Clark AR, Corbin B, et al. Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities. JCI Insight. 2018;3(4). doi:10.1172/jci.insight.95091
van Galen P, Hovestadt V, Ii MHW, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019;176(6):1265-1281.e24. doi:10.1016/j.cell.2019.01.031